Harnessing oncolytic virus-mediated immunity (Record no. 39758)

MARC details
000 -LEADER
fixed length control field 02108naaaa2200337uu 4500
001 - CONTROL NUMBER
control field https://directory.doabooks.org/handle/20.500.12854/49124
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20220219195012.0
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 978-2-88919-450-6
020 ## - INTERNATIONAL STANDARD BOOK NUMBER
International Standard Book Number 9782889194506
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.3389/978-2-88919-450-6
Terms of availability doi
041 0# - LANGUAGE CODE
Language code of text/sound track or separate title English
042 ## - AUTHENTICATION CODE
Authentication code dc
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Volker Schirrmacher
Relationship auth
245 10 - TITLE STATEMENT
Title Harnessing oncolytic virus-mediated immunity
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Frontiers Media SA
Date of publication, distribution, etc. 2015
300 ## - PHYSICAL DESCRIPTION
Extent 1 electronic resource (110 p.)
506 0# - RESTRICTIONS ON ACCESS NOTE
Terms governing access Open Access
Source of term star
Standardized terminology for access restriction Unrestricted online access
520 ## - SUMMARY, ETC.
Summary, etc. Oncolytic viruses (OVs) have emerged as a promising anticancer treatment. OVs selectively infect, replicate in, and kill tumor cells. Oncolytic viral therapy occurs in two phases: an initial phase where the virus mediates direct oncolysis of tumor cells, and a second phase where an induced post-oncolytic immune response continues to mediate tumor destruction and retards progression of the disease. For a long time, the therapeutic efficacy was thought to depend mainly on the direct viral oncolysis based on their tumor selective replication and killing activities. But the post-oncolytic anti-tumor activity induced by the OV therapy is also a key factor for an efficient therapeutic activity. The topic adresses various strategies how to optimize OVs anti-tumor activity.
540 ## - TERMS GOVERNING USE AND REPRODUCTION NOTE
Terms governing use and reproduction Creative Commons
Use and reproduction rights https://creativecommons.org/licenses/by/4.0/
Source of term cc
-- https://creativecommons.org/licenses/by/4.0/
546 ## - LANGUAGE NOTE
Language note English
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term anti-tumor activity
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term immunovirotherapy
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term oncolytic virus
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term oncolytic virotherapy
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term tumor-associated antigen
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term immunotherapeutic approaches
653 ## - INDEX TERM--UNCONTROLLED
Uncontrolled term anti-viral response
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Philippe Fournier
Relationship auth
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="http://journal.frontiersin.org/researchtopic/1613/harnessing-oncolytic-virus-mediated-antitumor-immunity">http://journal.frontiersin.org/researchtopic/1613/harnessing-oncolytic-virus-mediated-antitumor-immunity</a>
Access status 0
Public note DOAB: download the publication
856 40 - ELECTRONIC LOCATION AND ACCESS
Host name www.oapen.org
Uniform Resource Identifier <a href="https://directory.doabooks.org/handle/20.500.12854/49124">https://directory.doabooks.org/handle/20.500.12854/49124</a>
Access status 0
Public note DOAB: description of the publication

No items available.